Universitätsspital Zürich (USZ)

Hospital


Location: Zürich (Zurich), Switzerland (CH) CH

ISNI: 0000000404789977

ROR: https://ror.org/01462r250

Show on Map:


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

MICRORNA-125B REGULATES APOPTOSIS IN SYSTEMIC SCLEROSIS (2018) Kozlova A, Pachera E, Maurer B, Juengel A, Distler J, Kania G, Distler O Conference contribution RITUXIMAB IN SYSTEMIC SCLEROSIS : SAFETY AND EFFICACY DATA FROM THE EUSTAR NETWORK (2018) Elhai M, Distler O, Smith V, Matucci-Cerinic M, Alegre-Sancho JJ, Truchetet ME, Braun-Moscovici Y, et al. Conference contribution Racial differences in SSc disease presentation: a European scleroderma trials and research group (EUSTAR) study (2018) Jaeger VK, Siegert E, Hachulla E, Airo P, Valentini G, Matucci-Cerinic M, Scorza R, et al. Conference contribution Orphan Nuclear Receptor Ror alpha Is a Key Regulator of Tgf beta- and WNT-Signaling in Fibrotic Diseases (2018) Kagwiria R, Liang R, Matei AE, Sihler N, Chen CW, Burris T, Distler O, et al. Conference contribution LONG NONCODING RNA H19X IS A MASTER REGULATOR OF EXTRACELLULAR MATRIX PRODUCTION IN SYSTEMIC SCLEROSIS (2018) Pachera E, Assassi S, Salazar G, Frank-Bertoncelj M, Distler J, Kania G, Distler O Conference contribution FGFR3/FGF9 Regulates the Activity of Profibrotic Cytokine and Growth Factor Pathways to Drive Fibroblast Activation and Tissue Fibrosis in Systemic Sclerosis (2018) Summa L, Thuong Trinh-Minh , Chen CW, Soare A, Distler O, Schett G, Distler J, et al. Conference contribution Inhibition of Nuclear Receptor Coactivator 3 Attenuates Fibrosis in Murine Models of Systemic Sclerosis (2018) Pötter S, Dees C, Bergmann C, Distler O, Schett G, Distler J, Ramming A Conference contribution Patterns of chronic hand eczema: a semantic map analysis of the CARPE registry data (2018) Cazzaniga S, Apfelbacher C, Diepgen T, Ofenloch RF, Weisshaar E, Molin S, Bauer A, et al. Journal article Neuromuscular Side Effects of Immune Checkpoint Inhibitors (2018) Moreira A, Loquai C, Knauss S, Gutzmer R, Dimitriou F, Meier F, Heppt M, et al. Conference contribution FV03 MEK Inhibitors improved the Survival of NRAS-mutated Melanoma Patients by using Checkpoint Inhibitors: Results of a retrospective, multicenter Analysis of 364 Patients (2018) Kirchberger MC, Ugurel S, Mangana J, Heppt M, Eigentler T, Berking C, Schadendorf D, et al. Conference contribution